MY207205A - Cd3 antibody and pharmaceutical use thereof - Google Patents
Cd3 antibody and pharmaceutical use thereofInfo
- Publication number
- MY207205A MY207205A MYPI2021002766A MYPI2021002766A MY207205A MY 207205 A MY207205 A MY 207205A MY PI2021002766 A MYPI2021002766 A MY PI2021002766A MY PI2021002766 A MYPI2021002766 A MY PI2021002766A MY 207205 A MY207205 A MY 207205A
- Authority
- MY
- Malaysia
- Prior art keywords
- antibody
- cells
- tumor
- present disclosure
- pharmaceutical use
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present disclosure relates to a CD3 antibody and a pharmaceutical use thereof. Specifically, the present disclosure relates to forming a multi-specificity antibody by using CD3 antibody and binding molecules of another target. The multi-specificity antibody may simultaneously bind to CD3 and another tumor-associated antigen, and bind and activate CD3-positive T cells while binding tumor-associated antigen-expressing cells, thereby promoting T cells specifically killing tumor cells that express tumor-associated antigens. In addition, the present disclosure also provides a preparation and application of a multi- specific antibody. (FIGURE 1A)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811491781 | 2018-12-07 | ||
| PCT/CN2019/123548 WO2020114478A1 (en) | 2018-12-07 | 2019-12-06 | Cd3 antibody and pharmaceutical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY207205A true MY207205A (en) | 2025-02-06 |
Family
ID=70975360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021002766A MY207205A (en) | 2018-12-07 | 2019-12-06 | Cd3 antibody and pharmaceutical use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12258405B2 (en) |
| EP (1) | EP3892639A4 (en) |
| JP (1) | JP7461950B2 (en) |
| KR (1) | KR102952460B1 (en) |
| CN (2) | CN112955471B (en) |
| AU (1) | AU2019394241B2 (en) |
| BR (1) | BR112021010026A2 (en) |
| MX (1) | MX2021006389A (en) |
| MY (1) | MY207205A (en) |
| TW (1) | TWI821474B (en) |
| WO (1) | WO2020114478A1 (en) |
| ZA (1) | ZA202104518B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7641908B2 (en) * | 2019-03-29 | 2025-03-07 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Pharmaceutical composition containing an antibody against IL-5 and its use |
| TW202325743A (en) * | 2021-07-14 | 2023-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Antigen-binding molecule that specifically binds to cd38, bcma and cd3 and medical uses thereof |
| CN113527493B (en) * | 2021-07-20 | 2023-10-27 | 广州爱思迈生物医药科技有限公司 | A B7-H3 antibody and its application |
| EP4397685A4 (en) * | 2021-09-03 | 2025-10-22 | Novoprotein Scient Inc | HUMANIZED ANTI-CD3 ANTIBODY |
| CN116462765A (en) * | 2022-01-20 | 2023-07-21 | 上海君实生物医药科技股份有限公司 | Anti-CD3 and anti-CD20 bispecific antibodies and uses thereof |
| MX2024011128A (en) * | 2022-03-14 | 2024-09-18 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Antigen-binding molecule specifically binding to gprc5d and cd3 and medical use thereof. |
| CN115368464B (en) * | 2022-07-19 | 2025-06-10 | 合肥天港免疫药物有限公司 | Bispecific antibodies and their applications |
| CN115368462B (en) * | 2022-07-19 | 2026-01-02 | 合肥天港免疫药物有限公司 | Bispecific antibodies and their applications |
| CN115368465B (en) * | 2022-07-19 | 2026-02-24 | 合肥天港免疫药物有限公司 | Bispecific antibodies and uses thereof |
| KR20260051102A (en) * | 2023-07-07 | 2026-04-15 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | EGFR/C-MET bispecific binding protein and its uses |
| CN121443647A (en) * | 2023-07-07 | 2026-01-30 | 四川科伦博泰生物医药股份有限公司 | EGFR/c-MET Bispecific Binding Protein and Its Uses |
| CN119569886A (en) * | 2023-09-06 | 2025-03-07 | 合肥天港免疫药物有限公司 | Bispecific antibodies and uses thereof |
| WO2025056013A1 (en) * | 2023-09-13 | 2025-03-20 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition comprising bispecific antibody specifically binding to gprc5d and cd3 |
| CN122161833A (en) * | 2023-11-15 | 2026-06-05 | 四川科伦博泰生物医药股份有限公司 | Antibody-drug conjugates targeting EGFR/c-MET, their preparation methods and applications |
| WO2025131024A1 (en) * | 2023-12-22 | 2025-06-26 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition comprising bispecific antibody specifically binding dll3 and cd3 |
| WO2025245264A1 (en) * | 2024-05-21 | 2025-11-27 | Briapro Therapeutics Corp. | Anti-b7-h3 antibodies and methods of use thereof |
| CN122234224A (en) * | 2026-05-21 | 2026-06-19 | 济南微生态生物医学省实验室 | A nanobody targeting PSMA and its application |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| EP2352763B2 (en) * | 2008-10-01 | 2022-09-21 | Amgen Research (Munich) GmbH | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| KR101837053B1 (en) * | 2008-10-01 | 2018-03-12 | 암젠 리서치 (뮌헨) 게엠베하 | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalphaxcd3 bispecific single chain antibody |
| WO2012162067A2 (en) * | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| IN2014MN02293A (en) * | 2012-04-20 | 2015-08-07 | Emergent Product Dev Seattle | |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US10647768B2 (en) * | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| WO2016154585A1 (en) * | 2015-03-26 | 2016-09-29 | Charles Sentman | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| HK1253512A1 (en) * | 2015-05-29 | 2019-06-21 | Amphivena Therapeutics, Inc. | Methods of using bispecific cd33 and cd3 binding proteins |
| TWI744242B (en) * | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
| JP2018523686A (en) * | 2015-08-17 | 2018-08-23 | マクロジェニクス,インコーポレーテッド | Bispecific monovalent diabody capable of binding to B7-H3 and CD3 and uses thereof |
| MY195059A (en) * | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| EP3356407B1 (en) | 2015-10-02 | 2021-11-03 | F. Hoffmann-La Roche AG | Bispecific anti-cd19xcd3 t cell activating antigen binding molecules |
| CN106632681B (en) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | Anti- EGFR and AntiCD3 McAb bispecific antibody and its application |
| CN106589129B (en) * | 2016-12-30 | 2021-03-05 | 上海近岸生物科技有限公司 | Tri-functional molecule combined with CD19, CD3 and CD28 and application thereof |
| CN112969476B (en) * | 2018-12-07 | 2024-06-14 | 江苏恒瑞医药股份有限公司 | Multi-specific protein molecules |
-
2019
- 2019-12-06 TW TW108144713A patent/TWI821474B/en active
- 2019-12-06 EP EP19893440.8A patent/EP3892639A4/en active Pending
- 2019-12-06 CN CN201980072290.1A patent/CN112955471B/en active Active
- 2019-12-06 MX MX2021006389A patent/MX2021006389A/en unknown
- 2019-12-06 CN CN202211304269.XA patent/CN116396386A/en active Pending
- 2019-12-06 BR BR112021010026-1A patent/BR112021010026A2/en unknown
- 2019-12-06 KR KR1020217020182A patent/KR102952460B1/en active Active
- 2019-12-06 MY MYPI2021002766A patent/MY207205A/en unknown
- 2019-12-06 US US17/298,703 patent/US12258405B2/en active Active
- 2019-12-06 AU AU2019394241A patent/AU2019394241B2/en active Active
- 2019-12-06 WO PCT/CN2019/123548 patent/WO2020114478A1/en not_active Ceased
- 2019-12-06 JP JP2021531235A patent/JP7461950B2/en active Active
-
2021
- 2021-06-29 ZA ZA2021/04518A patent/ZA202104518B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3892639A4 (en) | 2022-08-24 |
| KR102952460B1 (en) | 2026-04-13 |
| BR112021010026A2 (en) | 2021-08-17 |
| CN116396386A (en) | 2023-07-07 |
| KR20210100654A (en) | 2021-08-17 |
| WO2020114478A1 (en) | 2020-06-11 |
| AU2019394241B2 (en) | 2026-04-09 |
| ZA202104518B (en) | 2023-01-25 |
| TWI821474B (en) | 2023-11-11 |
| CN112955471A (en) | 2021-06-11 |
| JP7461950B2 (en) | 2024-04-04 |
| MX2021006389A (en) | 2021-07-15 |
| TW202021987A (en) | 2020-06-16 |
| AU2019394241A1 (en) | 2021-06-03 |
| US20220242953A1 (en) | 2022-08-04 |
| CA3121565A1 (en) | 2020-06-11 |
| JP2022510322A (en) | 2022-01-26 |
| EP3892639A1 (en) | 2021-10-13 |
| CN112955471B (en) | 2022-11-22 |
| US12258405B2 (en) | 2025-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006389A (en) | Cd3 antibody and pharmaceutical use thereof. | |
| WO2020052692A3 (en) | Binding molecules against cd3 and uses thereof | |
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| MX2022015823A (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof. | |
| PH12018501611A1 (en) | Antigen binding proteins thant bind pd-l1 | |
| ZA201803079B (en) | Anti-dr5 antibodies and methods of use thereof | |
| AU2018253589A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| PH12020500667A1 (en) | Multispecific antibodies and use thereof | |
| PH12018502478A1 (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
| MX2020004410A (en) | Antibody compositions for tumor treatment. | |
| EP4295918A3 (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
| AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
| EA201990171A1 (en) | SPECIFIC ANTIBODY AGAINST EGFR AND AGAINST CD3 AND ITS APPLICATION | |
| PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
| MY193013A (en) | Bispecific antibodies with tetravalency for a costimulatory tnf receptor | |
| WO2013188693A8 (en) | Antigen binding constructs to cd3 | |
| HUE073077T2 (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
| AU2018338322A1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| PH12019501089A1 (en) | Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same | |
| AU2019433019A8 (en) | Antibodies binding CD40 and uses thereof | |
| ZA202008095B (en) | Humanized antibodies against psma | |
| MX2023004275A (en) | Anti-pd-1/cd40 bispecific antibodies and uses thereof. | |
| MX2025002569A (en) | Anti-trop2/egfr antibodies and uses thereof | |
| MX2020008730A (en) | B7-H4 ANTIBODY DOSING REGIMENS. | |
| MX2024009292A (en) | Anti-her2/trop2 antibodies and uses thereof. |